General Pharmaceutical Council determination — substantive hearing
GPhC ordered Muhammad Qasim Ali Manzoor's removal over medicine supplies in 2024
The committee found that medicines were supplied knowing they were very likely to be abused. It found impaired fitness to practise and directed removal from the register, with interim suspension.
MedicWatch editorial · Published 24 May 2024 · Updated 22 September 2026
Erasure (struck off the register)
Data last checked: 22 September 2026Report a correction
What does “struck off the register” mean?
The regulator directed removal from the register in this decision. The decision explains when the direction takes effect and any appeal provisions. Check the official register for the practitioner's current registration status.
Concerning Muhammad Qasim Ali Manzoor, pharmacist (General Pharmaceutical Council 2203578).
Decision date: 24 May 2024 · Hearing started 22 May 2024 and ended 24 May 2024
In plain English
The GPhC committee directed Muhammad Qasim Ali Manzoor's removal from the pharmacists' register in May 2024. It found that he supplied medicines to another pharmacist knowing they were very likely to be abused. The committee found serious misconduct and impaired fitness to practise, with limited insight and no demonstrated remediation. It also imposed interim suspension pending removal taking effect.
Charges
The allegations concerned offering and supplying codeine linctus and Phenergan to another pharmacist between 2017 and 2020 without clinical need, knowing or believing that the medicines would likely be abused or misused.
Findings
The committee found all allegations proved, serious misconduct and impaired fitness to practise. It found that the pharmacist knew the medicines were very likely to be abused, and identified limited insight, no demonstrated remediation and continuing risk. It did not find sufficient evidence to conclude that his integrity could no longer be relied upon. It directed removal from the register and imposed interim suspension pending removal taking effect.
Mitigating and aggravating factors
Mitigating factors
a. The Registrant has no previous fitness to practice findings; b. There is no evidence to suggest the Registrant has repeated his actions since March 2020.
Aggravating factors
a. The Registrant’s misconduct spanned a period of three years; b. The Registrant had sold controlled drugs c. The Registrant had contravened standards relating to patient safety d. The Registrant had sold drugs knowing that they were to be abused in the form of a drug known as Lean.
Source
All facts on this page are drawn from the publicly published General Pharmaceutical Council determination linked below. MedicWatch does not editorialise the regulator’s findings.
Spot something incorrect?
If a fact on this page is wrong, or you believe the page should not be published, please submit a correction or takedown request.